Analysis finds bariatric surgery volume down 13% as GLP-1 use climbs 67%

Bariatric surgery volume dropped 13% over the past year while the number of health plan members taking GLP-1 medications rose 67% over the past two years, according to a new analysis from Cedar Gate Technologies, an IQVIA business, released February 18, 2026 ^[1]. The firm described the pattern as "a notable shift toward nonsurgical weight loss treatments" ^[1].

The analysis also compared what each option costs. In 2024, the average cost of bariatric surgery was $24,215, a 9.62% increase over the prior year ^[1]. The average annual cost per patient for GLP-1 prescriptions was roughly $5,200, up 8.33% from 2023 ^[1].

That gap — about $24,000 for a one-time procedure versus roughly $5,200 per year for medication — is the number employers and insurers are watching. Surgery is a single large expense. A GLP-1 prescription repeats every year a person stays on it. At approximately $5,200 annually, a patient would reach the cost of an average bariatric surgery in a little under five years of continuous treatment, based on the figures in the analysis ^[1]. The analysis itself does not draw that comparison over a fixed number of years, and Cedar Gate's release is titled in part "but Long-Term Benefits Remain Unclear" ^[1].

Several details are not available in the material released so far. The analysis does not specify, in what has been published, how many people were in the studied population, which insurers or employers contributed the claims data, which GLP-1 products were included, or what share of members starting a GLP-1 were still filling prescriptions a year later ^[1]. It also does not report whether the people now taking GLP-1s would have qualified for or chosen surgery, so the 13% surgery decline and the 67% rise in drug use are described as occurring alongside each other rather than proven to be cause and effect ^[1]. The two figures also cover different periods — one year for the surgery decline, two years for the growth in GLP-1 users ^[1].

Why it matters for patients

Cost comparisons like this one tend to shape coverage decisions before they show up in any exam room conversation. When a payer sees a durable one-time expense on one side and an open-ended annual expense on the other, that math can influence prior authorization rules, step therapy requirements, or whether GLP-1s for weight loss are covered at all. Nothing in this analysis announces a coverage change ^[1], but it is the kind of data that informs one.

The finding also reflects something patients are already living. Bariatric surgery volume is falling ^[1], which suggests that people who once might have pursued a procedure are trying medication instead — a less invasive option that is also reversible in the sense that stopping it is possible, though the analysis does not address what happens to weight after people stop ^[1].

The phrase "long-term benefits remain unclear" in the title of Cedar Gate's release is worth noting ^[1]. Bariatric surgery has decades of outcome data behind it. GLP-1s for obesity are newer in wide use, and this analysis does not report head-to-head outcomes such as weight maintained at five or ten years, complication rates, or downstream medical spending for either group ^[1]. Anyone weighing the two approaches is doing so with more evidence on one side than the other, and that is a conversation for a clinician rather than a claims database.

What happens next

Cedar Gate published the analysis on February 18, 2026 ^[1]. The company has not announced, in the material available, a follow-up report, a peer-reviewed publication, or a timeline for releasing the underlying methodology ^[1]. Whether the 13% decline in surgeries continues, levels off, or reverses — particularly as lower-cost or oral GLP-1 options reach the market — is not addressed in this analysis and is not yet known.